Last €29.48 EUR
Change Today +0.54 / 1.85%
Volume 0.0
I7G On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
OTC US
Stuttgart
As of 10:14 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

ipsen (I7G) Snapshot

Open
€28.95
Previous Close
€28.95
Day High
€29.74
Day Low
€28.71
52 Week High
12/2/13 - €34.59
52 Week Low
04/22/13 - €25.02
Market Cap
2.4B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
82.8M
EX-Date
06/9/14
P/E TM
--
Dividend
€0.80
Dividend Yield
2.71%
Current Stock Chart for IPSEN (I7G)

Related News

No related news articles were found.

ipsen (I7G) Related Businessweek News

View More BusinessWeek News

ipsen (I7G) Details

Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; Adenuric for the treatment of gout; and Exforge which is used in the treatment of hypertension. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Décapepty. The company was founded in 1929 and is based in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,602 Employees
Last Reported Date: 03/26/14
Founded in 1929

ipsen (I7G) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.1M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: --
Compensation as of Fiscal Year 2012.

ipsen (I7G) Key Developments

Ipsen Announces First Set of Results on Positive Phase III Clinical Study of Dysport(R) in the Treatment of Adults Suffering from Upper Limb Spasticity

Ipsen announced that a first set of results on phase III clinical study of Dysport(R) in the treatment of adults suffering from Upper Limb Spasticity was presented at the 8(th) World Congress for NeuroRehabilitation in Istanbul (Turkey). Four weeks after Dysport(R) injection, the Phase III clinical study results demonstrated that: Patients treated with Dysport(R) showed a statistically significantly (p<0.0001) higher proportion of responders in muscle tone improvement versus placebo (i.e. exhibiting >=1 point improvement as measured by the Modified Ashworth Scale, MAS). At week 4, patients treated with Dysport(R) 500 units and 1000 units showed responding rates of 73.8% and 78.5%, respectively, compared to 22.8% in the placebo arm; Patients treated with Dysport(R) showed a statistically significant (p<0.0001) higher clinical benefit versus placebo, as measured by the Physician Global Assessment (PGA). At week 4, the mean PGA score for patients treated with Dysport(R) 500 units and 1000 units were 1.4 and 1.8, respectively, compared to 0.6 in the placebo arm. Additionally, patients treated with Dysport(R) showed a higher proportion of responders from baseline in improved passive function versus placebo (exhibiting >=1 grade decrease as measured by the disability assessment scale). At week 4, patients treated with Dysport(R) 1000 units showed a statistically significant response rate of 62%. Patients treated with Dysport(R) 500 units showed a clinically relevant response rate of 50%. Placebo arm showed a 39% response rate. The safety profile observed in the study was consistent with the known safety profile of Dysport(R).

Ipsen S.A. Announces Positive Results from Neurogenic Detrusor Overactivity

Ipsen S.A. announced positive results from its phase IIa clinical trial assessing Dysport(R) in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics. These results were achieved with a single dose of Dysport(R) 750 Units injected in either 15 or 30 sites in the detrusor muscle. Efficacy was confirmed by improvement in urodynamic parameters and quality of life. The safety profile observed in the study is consistent with the safety profile expected in this indication. This phase IIa, multinational, randomised, placebo-controlled study aimed to investigate the efficacy and safety of one cycle of a single dose of 750 U Dysport(R) in 47 patients with NDO secondary to Multiple Sclerosis (MS) or Spinal Cord Injury (SCI). Follow-up duration was of 96 days. The primary endpoint was the mean change from baseline in daily urinary incontinence episodes frequency 12 weeks after the injection for each administration mode, that is 15 or 30 injections points at a constant volume by injection site. Secondary endpoints included other clinical endpoints, urodynamic measurements, and safety.

Ipsen S.A. Proposes Payment of Dividend for the Fiscal 2013; Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2013; Provides Financial Targets for 2014

Ipsen's board of directors, which met on 27 February 2014, has decided to propose at the company's annual shareholders' meeting to be held on 4 June 2014 the payment of a dividend of EUR 0.80 per share, stable year-on-year, representing a pay-out ratio of approximately 44% of recurring adjusted consolidated net profit (attributable to the group's shareholders), compared to a pay-out ratio of approximately 46% for the 2012 financial year. The company reported audited consolidated earnings results for the year ended December 31, 2013. For the period, the company reported total revenues of EUR 1,281.8 million compared to EUR 1,277.4 million for the same period a year ago. Operating income was EUR 190.7 million compared to EUR 117.1 million last year. Recurring adjusted operating profit was EUR 208.6 million compared to EUR 198.3 million last year. Net profit from continuing operations was EUR 142.2 million or EUR 1.70 per diluted share compared to EUR 97.4 million or EUR 1.16 per basic share last year. Consolidated net profit attributable to shareholders of Ipsen S.A. was EUR 152.5 million or EUR 1.83 per diluted share compared to consolidated net loss attributable to shareholders of EUR 27.9 million or EUR 0.33 per diluted share last year. Net cash provided by operating activities profit was EUR 188.1 million compared to EUR 144.2 million last year. Acquisition of property, plant & equipment profit was EUR 42.0 million compared to EUR 49 million last year. Acquisition of intangible assets profit was EUR 20.4 million compared to EUR 33.8 million last year. Based on information currently available, the Group has set the following financial targets for 2014: Specialty Care drug sales growth year-on-year between 4.0% and 6.0%, driven by normalization of situation in the China, in a context of continued pricing pressure and uncertainty on Increlex(R) US resupply. Primary Care drug sales decline year-on-year between -2.0% and 0.0%, excluding the launch of a Smecta(R) generic in France. Recurring adjusted operating margin between [16.0%; 17.0%] of sales. In 2014, Ipsen will continue to implement operating efficiency measures. The Group notably strives to limit the profitability impact of launching Somatuline(R) NET in the US.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I7G:GR €29.48 EUR +0.54

I7G Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €10.80 EUR -0.03
Meda AB kr111.00 SEK +0.60
Orion OYJ €21.97 EUR +0.46
Procter & Gamble Hygiene & Health Care Ltd 3,402 INR +190.15
Recordati SpA €11.76 EUR -0.01
View Industry Companies
 

Industry Analysis

I7G

Industry Average

Valuation I7G Industry Range
Price/Earnings 17.1x
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow 15.4x
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.